Slough, United Kingdom

Joanna Rachel Thorne


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **The Innovative Contributions of Joanna Rachel Thorne**

Introduction

Joanna Rachel Thorne is a distinguished inventor based in Slough, GB, known for her significant contributions to the field of pharmaceuticals. She holds one patent that showcases her innovation in developing thieno-pyridine derivatives, which have potential therapeutic applications in various medical conditions.

Latest Patents

Joanna's patent, titled "Thieno-pyridine derivatives as MEK inhibitors," encompasses a series of thieno[2,3-b]pyridine derivatives. These compounds are designed with a unique structure where a substituted anilino moiety of the 2-position is linked with a carbonyl group connected to a pyrrolidin-1-yl ring. This chemical configuration enables the derivatives to selectively inhibit human MEK (MAPKK) enzymes, offering benefits in treating inflammatory, autoimmune, cardiovascular, proliferative (including oncological), and nociceptive conditions.

Career Highlights

Throughout her career at UCB Pharma, S.A., Joanna has made remarkable strides in pharmaceutical innovation. Her work focuses on developing novel therapeutic agents that address critical healthcare challenges. Joanna's background and expertise contribute significantly to ongoing research aimed at advancing medical treatments, reflecting her dedication to improving patient outcomes.

Collaborations

Joanna collaborates with talented professionals, including colleagues like James Andrew Johnson and Daniel Christopher Brookings. Together, they foster an environment of innovation and creativity, pushing the boundaries of pharmaceutical research to develop effective treatment options.

Conclusion

In conclusion, Joanna Rachel Thorne stands out as a pioneering inventor in the pharmaceutical industry. Her patent on thieno-pyridine derivatives highlights her commitment to innovation and the potential to improve patient care through targeted therapies. As she continues her work at UCB Pharma, her contributions will undoubtedly shape the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…